Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus rating of “Moderate Buy” by the ten research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $6.8571.

Several brokerages have recently weighed in on NMRA. Guggenheim restated a “buy” rating and issued a $14.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Mizuho lowered their target price on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, June 18th. Needham & Company LLC dropped their price target on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Tuesday, April 21st. Finally, HC Wainwright reduced their price objective on shares of Neumora Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock opened at $1.68 on Monday. The stock has a market capitalization of $311.27 million, a PE ratio of -1.26 and a beta of 2.74. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. Neumora Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.65. The business has a 50 day simple moving average of $1.74 and a 200-day simple moving average of $2.18.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. Equities analysts predict that Neumora Therapeutics will post -0.93 earnings per share for the current year.

Institutional Trading of Neumora Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC bought a new stake in Neumora Therapeutics during the fourth quarter worth approximately $27,000. Virtu Financial LLC bought a new position in shares of Neumora Therapeutics in the third quarter valued at $31,000. Legacy Private Trust Co. increased its holdings in shares of Neumora Therapeutics by 35.7% in the fourth quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock valued at $34,000 after buying an additional 5,000 shares in the last quarter. Fred Alger Management LLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $40,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Neumora Therapeutics during the 3rd quarter valued at $44,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.